MS
JBIO

Maven Securities’s Jade Biosciences JBIO Stock Holding History

Maven Securities’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
+50,000
New +$1.04M 0.02% 268
2021
Q3 		– Sell
-282
Closed -$225K – 1053
2021
Q2 		$225K Buy
+282
New +$225K 0.01% 909

Other funds holding JBIO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Maven Securities's JBIO Position: Q2 2026 in Review

Maven Securities opened a new position in Jade Biosciences (JBIO) in Q2 2026: 50,000 shares worth $1.11M. The stake represents 0.02% of the portfolio and ranks #268 among its holdings. This is a return to the name: Maven Securities previously reported a position in JBIO as recently as Q2 2021.

Maven Securities first reported a position in JBIO in Q2 2021 and has held it in 2 quarters since. 154 funds tracked by Wall St. Rank hold JBIO as of Q2 2026.

  • Maven Securities held 50,000 shares of Jade Biosciences worth $1.11M as of Q2 2026.
  • Jade Biosciences was a new Maven Securities position in Q2 2026.
  • Jade Biosciences made up 0.02% of Maven Securities's portfolio in Q2 2026, its #268 holding.
  • Maven Securities first reported a position in Jade Biosciences in Q2 2021 and has held it in 2 quarters since.
  • 154 funds tracked by Wall St. Rank held Jade Biosciences as of Q2 2026.

Based on Maven Securities's 13F filing for Q2 2026, filed 14 Aug 2026.